EAACI Biologicals Guidelines-Recommendations for severe asthma.
GRADE
biologicals
cost-effectiveness
guidelines
severe asthma
Journal
Allergy
ISSN: 1398-9995
Titre abrégé: Allergy
Pays: Denmark
ID NLM: 7804028
Informations de publication
Date de publication:
01 2021
01 2021
Historique:
received:
14
05
2020
accepted:
19
05
2020
pubmed:
3
6
2020
medline:
15
5
2021
entrez:
3
6
2020
Statut:
ppublish
Résumé
Severe asthma imposes a significant burden on patients, families and healthcare systems. Management is difficult, due to disease heterogeneity, co-morbidities, complexity in care pathways and differences between national or regional healthcare systems. Better understanding of the mechanisms has enabled a stratified approach to the management of severe asthma, supporting the use of targeted treatments with biologicals. However, there are still many issues that require further clarification. These include selection of a certain biological (as they all target overlapping disease phenotypes), the definition of response, strategies to enhance the responder rate, the duration of treatment and its regimen (in the clinic or home-based) and its cost-effectiveness. The EAACI Guidelines on the use of biologicals in severe asthma follow the GRADE approach in formulating recommendations for each biological and each outcome. In addition, a management algorithm for the use of biologicals in the clinic is proposed, together with future approaches and research priorities.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
14-44Informations de copyright
© 2020 EAACI and John Wiley and Sons A/S. Published by John Wiley and Sons Ltd.
Références
Global Burden of Disease 2016 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet. 2016;2017(390):1211-1259.
https://ginasthma.org/wp-content/uploads/2020/04/GINA-2020-full-report_-final-_wms.pdf. Accessed April 10, 2020
Hekking PP, Wener RR, Amelink M, Zwinderman AH, Bouvy ML, Bel EH. The prevalence of severe refractory asthma. J Allergy Clin Immunol. 2015;135:896-902.
Corren J, Yawn BP. Advancing the care of severe asthma: differential diagnosis, multidisciplinary management, and patient engagement [published online ahead of print, 2019 Feb 20]. Am J Med. 2019. https://doi.org/10.1016/j.amjmed.2019.02.002
Tay TR, Hew M. Comorbid, “treatable traits” in difficult asthma: current evidence and clinical evaluation. Allergy. 2018;73:1369-1382.
Bender BG. Sorting out nonadherence and airway inflammation in treatment escalation for severe asthma. Am J Respir Crit Care Med. 2019;199:400-402.
Lee J, Tay TR, Radhakrishna N, et al. Nonadherence in the era of severe asthma biologics and thermoplasty. Eur Respir J. 2018;51:1701836.
Settipane RA, Kreindler JL, Chung Y, Tkacz J. Evaluating direct costs and productivity losses of patients with asthma receiving GINA 4/5 therapy in the United States. Ann Allergy Asthma Immunol. 2019;123(6):564-572.
Ortega H, Hahn B, Tran JN, et al. Disease burden in patients with asthma before initiating biologics: a retrospective cohort database study. Allergy Asthma Proc. 2019;40(3):146-153.
Chen S, Golam S, Myers J, et al. Systematic literature review of the clinical, humanistic, and economic burden associated with asthma uncontrolled by GINA Steps 4 or 5 treatment. Curr Med Res Opin. 2018;34(12):2075-2088.
Perez de Llano L, Martinez-Moragon E, Plaza Moral V, et al. Unmet therapeutic goals and potential treatable traits in a population of patients with severe uncontrolled asthma in Spain. ENEAS study. Respir Med. 2019;151:49-54.
Canonica GW, Colombo GL, Bruno GM, et al. Shadow cost of oral corticosteroids-related adverse events: a pharmacoeconomic evaluation applied to real-life data from the Severe Asthma Network in Italy (SANI) registry. World Allergy Organ J. 2019;12(1):100007.
Barry LE, Sweeney J, O'Neill C, Price D, Heaney LG. The cost of systemic corticosteroid-induced morbidity in severe asthma: a health economic analysis. Respir Res. 2017;18:129.
Bourdin A, Fabry-Vendrand C, Ostinelli J, et al. the burden of severe asthma in France: a case-control study using a medical claims database. J Allergy Clin Immunol Pract. 2019;7(5):1477-1487.
Ahmed H, Turner S. Severe asthma in children-a review of definitions, epidemiology, and treatment options in 2019. Pediatr Pulmonol. 2019;54(6):778-787.
Fleming L, Murray C, Bansal AT, et al. The burden of severe asthma in childhood and adolescence: results from the paediatric U-BIOPRED cohorts. Eur Respir J. 2015;46:1322-1333.
Selby L, Saglani S. Severe asthma in children: therapeutic considerations. Curr Opin Allergy Clin Immunol. 2019;19(2):132-140.
McGeachie MJ, Yates KP, Zhou X, et al. Patterns of growth and decline in lung function in persistent childhood asthma. N Engl J Med. 2016;374(19):1842-1852.
Bui DS, Lodge CJ, Burgess JA, et al. Childhood predictors of lung function trajectories and future COPD risk: a prospective cohort study from the first to the sixth decade of life. Lancet Respir Med. 2018;6(7):535-544.
Chung KF, Wenzel SE, Brozek JL, et al. International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma. Eur Respir J. 2014;43:343-373.
Holguin F, Cardet JC, Chung KF, et al. Management of severe asthma: a European Respiratory Society/American Thoracic Society guideline. Eur Respir J. 2020;55(1):1900588.
Difficult-to-treat and Severe Asthma in Adolescent and Adult Patients. Diagnosis and Management. A GINA Pocket Guide for Health Professionals. 2018. https://ginasthma.org/wp-content/uploads/2018/11/GINA-SA-FINAL-wms.pdf.
Anderson GP. Endotyping asthma: new insights into key pathogenic mechanisms in a complex, heterogeneous disease. Lancet. 2008;372(9643):1107-1119.
Lötvall J, Akdis CA, Bacharier LB, et al. Asthma endotypes: a new approach to classification of disease entities within the asthma syndrome. J Allergy Clin Immunol. 2011;127(2):355-360.
Agache I, Akdis C, Jutel M, Virchow JC. Untangling asthma phenotypes and endotypes. Allergy. 2012;67(7):835-846.
Agache IO. From phenotypes to endotypes to asthma treatment. Curr Opin Allergy Clin Immunol. 2013;13(3):249-256.
Agache I, Akdis CA. Endotypes of allergic diseases and asthma: An important step in building blocks for the future of precision medicine. Allergol Int. 2016;65(3):243-252.
Agache I, Akdis CA. Precision medicine and phenotypes, endotypes, genotypes, regiotypes, and theratypes of allergic diseases. J Clin Invest. 2019;130:1493-1503.
Gibson PG, McDonald VM. Management of severe asthma: targeting the airways, comorbidities and risk factors. Intern Med J. 2017;47(6):623-631.
Chung KF, Adcock IM. Precision Medicine for the discovery of treatable mechanisms in severe asthma. Allergy. 2019;74(9):1649-1659.
Agache I. Severe asthma phenotypes and endotypes. Semin Immunol. 2019;46:101301.
Agache I, Sugita K, Morita H, et al. The complex type 2 endotype in allergy and asthma: from laboratory to bedside. Curr Allergy Asthma Rep. 2015;15(6):29.
Liu AH, Babineau DC, Krouse RZ, et al. Pathways through which asthma risk factors contribute to asthma severity in inner-city children. J Allergy Clin Immunol. 2016;138(4):1042-1050.
Pongracic JA, Krouse RZ, Babineau DC, et al. Distinguishing characteristics of difficult-to-control asthma in inner-city children and adolescents. J Allergy Clin Immunol. 2016;138(4):1030-1041.
Bossley CJ, Fleming L, Gupta A, et al. Pediatric severe asthma is characterized by eosinophilia and remodeling without T(H)2 cytokines. J Allergy Clin Immunol. 2012;129:974-978.
Saglani S. Childhood severe asthma: New insights on remodelling and biomarkers. Paediatr Respir Rev. 2017;24:11-13.
Teague WG, Phillips BR, Fahy JV, et al. Baseline features of the severe asthma research program (SARP III) cohort: differences with age. J Allergy Clin Immunol Pract. 2018;6:545-554.
Nayeem SS, Bush A, Silveira LP, et al. Clinical and pathological characteristics of severely asthmatic children with persistent airflow limitation. Thorax. 2017;72:A45-A46.
Andersson CK, Adams A, Nagakumar P, et al. Intraepithelial neutrophils in pediatric severe asthma are associated with better lung function. J Allergy Clin Immunol. 2017;139:1819-1829.
Saglani S, Lui S, Ullmann N, et al. IL-33 promotes airway remodeling in pediatric patients with severe steroid-resistant asthma. J Allergy Clin Immunol. 2013;132:676-685.
Nagakumar P, Denney L, Fleming L, et al. Type 2 innate lymphoid cells in induced sputum from children with severe asthma. J Allergy Clin Immunol. 2016;137:624-626.
Bousquet J, Brusselle G, Buhl R, et al. Care pathways for the selection of a biologic in severe asthma. Eur Respir J. 2017;50(6):1701782.
Papadopoulos NG, Barnes P, Canonica GW, et al. The evolving algorithm of biological selection in severe asthma. Allergy. 2020;75:1555-1563. https://doi.org/10.1111/all.14256
Seys SF, Quirce S, Agache I, et al. Severe asthma: Entering an era of new concepts and emerging therapies: Highlights of the 4th international severe asthma forum, Madrid, 2018. Allergy. 2019;74(11):2244-2248.
Agache I, Cojanu C, Laculiceanu A, Rogozea L. Critical Points on the Use of Biologicals in Allergic Diseases and Asthma. Allergy Asthma Immunol Res. 2020;12(1):24-41.
Diamant Z, Vijverberg S, Alving K, et al. Towards clinically applicable biomarkers for asthma - an EAACI position paper. Allergy. 2019;74(10):1835-1851.
Agache I, Rogozea L. Asthma biomarkers: do they bring precision medicine closer to the clinic? Allergy Asthma Immunol Res. 2017;9(6):466-476.
Agache I, Annesi-Maesano I, Bonertz A, et al. Prioritizing research challenges and funding for allergy and asthma and the need for translational research-The European Strategic Forum on Allergic Diseases. Allergy. 2019;74(11):2064-2076.
Hinks TSC, Brown T, Lau LCK, et al. Multidimensional endotyping in patients with severe asthma reveals inflammatory heterogeneity in matrix metalloproteinases and chitinase 3-like protein 1. J Allergy Clin Immunol. 2016;138(1):61-75.
Agache I, Strasser DS, Pierlot GM, et al. Monitoring inflammatory heterogeneity with multiple biomarkers for multidimensional endotyping of asthma. J Allergy Clin Immunol. 2018;141(1):442-445.
Anderson WC 3rd, Szefler SJ. Cost-effectiveness and comparative effectiveness of biologic therapy for asthma: to biologic or not to biologic? Ann Allergy Asthma Immunol. 2019;122(4):367-372.
Boyman O, Kaegi C, Akdis M, et al. EAACI IG Biologicals task force paper on the use of biologic agents in allergic disorders. Allergy. 2015;70(7):727-754.
https://www.ema.europa.eu/en/medicines/human/EPAR/fasenra. Accessed December 16, 2019.
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/761070Orig1s000Approv.pdf. Accessed December 16, 2019.
https://www.ema.europa.eu/en/medicines/human/summaries-opinion/dupixent-0. Accessed December 16, 2019.
https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/761055s007lbl.pdf. Accessed December 16, 2019.
https://www.ema.europa.eu/en/medicines/human/EPAR/nucala. Accessed December 16, 2019.
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/761122s000lbl.pdf. Accessed December 16, 2019.
https://www.ema.europa.eu/en/medicines/human/EPAR/xolair. Accessed December 16, 2019.
https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/103976s5225lbl.pdf. Accessed December 16, 2019.
https://www.ema.europa.eu/en/medicines/human/EPAR/cinqaero. Accessed December 16, 2019.
https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/761033lbl.pdf. Accessed December 16, 2019.
Agache I, Beltran J, Akdis C, et al. Efficacy and safety of treatment with biologicals (benralizumab, dupilumab, mepolizumab, omalizumab and reslizumab) for severe eosinophilic asthma: A systematic review for the EAACI Guidelines - recommendations on the use of biologicals in severe asthma. Allergy. 2020;75(5):1023-1042. https://doi.org/10.1111/all.14221
Agache I, Rocha C, Beltran J, et al. Efficacy and safety of treatment with biologicals (benralizumab, dupilumab and omalizumab) for severe allergic asthma: A systematic review for the EAACI Guidelines - recommendations on the use of biologicals in severe asthma. Allergy. 2020;75:1043-1057. https://doi.org/10.1111/all.14235
Agache I, Song Y, Rocha C, et al. Efficacy and Safety of treatment with dupilumab for severe asthma: A systematic review of the EAACI guidelines - Recommendations on the use of biologicals in severe asthma. Allergy. 2020;75(5):1058-1068. https://doi.org/10.1111/all.14268
Walford HH, Doherty TA. Diagnosis and management of eosinophilic asthma: a US perspective. J Asthma Allergy. 2014;7:53-65.
Santanello NC, Zhang J, Seidenberg B, Reiss TF, Barber BL. What are minimal important changes for asthma measures in a clinical trial? Eur Respir J. 1999;14(1):23-27.
Jones PW. Interpreting thresholds for a clinically significant change in health status in asthma and COPD. Eur Respir J. 2002;19(3):398-404.
Juniper EF, Svensson K, Mörk AC, Ståhl E. Measurement properties and interpretation of three shortened versions of the asthma control questionnaire. Respir Med. 2005;99(5):553-558.
Dweik RA, Boggs PB, Erzurum SC, et al. American Thoracic Society Committee on Interpretation of Exhaled Nitric Oxide Levels (FENO) for Clinical Applications. An official ATS clinical practice guideline: interpretation of exhaled nitric oxide levels (FENO) for clinical applications. Am J Respir Crit Care Med. 2011;184(5):602-615.
Guyatt GH, Oxman AD, Vist GE, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ. 2008;336(7650):924.
Guyatt G, Oxman AD, Akl EA, et al. GRADE guidelines: Introduction-GRADE evidence profiles and summary of findings tables. J Clin Epidemiol. 2011;64(4):383-394.
https://apps.who.int/iris/bitstream/handle/10665/75146/9789241548441_eng.pdf;jsessionid=CA74A1F992AE5574F7B899567C721BC1?sequence=1. Accessed February 2, 2020.
Kolbeck R, Kozhich A, Koike M, et al. MEDI-563, a humanized anti-IL-5 receptor alpha mAb with enhanced antibody-dependent cell-mediated cytotoxicity function. J Allergy Clin Immunol. 2010;125:1344-1353.
Dávila González I, Moreno Benítez F, Quirce S. Benralizumab: a new approach for the treatment of severe eosinophilic asthma. J Investig Allergol Clin Immunol. 2019;29(2):84-93.
Laviolette M, Gossage DL, Gauvreau G, et al. Effects of benralizumab on airway eosinophils in asthmatic patients with sputum eosinophilia [published correction appears in J Allergy Clin Immunol. 2014;133(4): 1232]. J Allergy Clin Immunol. 2013;132(5):1086-1096.e5.
Panettieri RA Jr, Welte T, Shenoy KV, et al. Onset of effect, changes in airflow obstruction and lung volume, and health-related quality of life improvements with benralizumab for patients with severe eosinophilic asthma: phase IIIb randomized, controlled trial (SOLANA). J Asthma Allergy. 2020;13:115-126.
Chupp G, Lugogo NL, Kline JN, et al. Rapid onset of effect of benralizumab on morning peak expiratory flow in severe, uncontrolled asthma. Ann Allergy Asthma Immunol. 2019;122(5):478-485.
Bleecker ER, FitzGerald JM, Chanez P, et al. Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting β2-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial. Lancet. 2016;388(10056):2115-2127.
FitzGerald JM, Bleecker ER, Nair P, et al. Benralizumab, an anti-interleukin-5 receptor α monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2016;388(10056):2128-2141.
Nair P, Wenzel S, Rabe KF, et al. Oral glucocorticoid-sparing effect of benralizumab in severe asthma. N Engl J Med. 2017;376(25):2448-2458.
Palomares Ó, Sánchez-Ramón S, Dávila I, et al. dIvergEnt: how IgE axis contributes to the continuum of allergic asthma and anti-IgE therapies. Int J Mol Sci. 2017;18(6):1328.
Agache I, Strasser DS, Klenk A, et al. Serum IL-5 and IL-13 consistently serve as the best predictors for the blood eosinophilia phenotype in adult asthmatics. Allergy. 2016;71(8):1192-1202.
Chipps BE, Newbold P, Hirsch I, Trudo F, Goldman M. Benralizumab efficacy by atopy status and serum immunoglobulin E for patients with severe, uncontrolled asthma. Ann Allergy Asthma Immunol. 2018;120(5):504-511.
Gour N, Wills-Karp M. IL-4 and IL-13 signaling in allergic airway disease. Cytokine. 2015;75:68-78.
Marone G, Granata F, Pucino V, et al. The intriguing role of interleukin 13 in the pathophysiology of asthma. Front Pharmacol. 2019;10:1387.
Alasandagutti ML, Ansari MS, Sagurthi SR, Valluri V, Gaddam S. Role of IL-13 genetic variants in signalling of asthma. Inflammation. 2017;40(2):566-577.
McDowell PJ, Heaney LG. Different endotypes and phenotypes drive the heterogeneity in severe asthma. Allergy. 2020;75(2):302-310.
Junttila IS. Tuning the cytokine responses: an update on interleukin (IL)-4 and IL-13 receptor complexes. Front Immunol. 2018;9:888.
Le Floc’h A, Allinne J, Nagashima K, et al. Dual blockade of IL-4 and IL-13 with dupilumab, an IL-4Rα antibody, is required to broadly inhibit type 2 inflammation. Allergy. 2020;75:1188-1204.
Matsunaga K, Katoh N, Fujieda S, Izuhara K, Oishi K. Dupilumab: Basic aspects and applications to allergic diseases [published online ahead of print, 2020 Jan 29]. Allergol Int. 2020;S1323-8930(20):30008-30013.
Wenzel S, Castro M, Corren J, et al. Dupilumab efficacy and safety in adults with uncontrolled persistent asthma despite use of medium-to-high-dose inhaled corticosteroids plus a long-acting β2 agonist: a randomised double-blind placebo-controlled pivotal phase 2b dose-ranging trial. Lancet. 2016;388(10039):31-44.
Castro M, Corren J, Pavord ID, et al. Dupilumab efficacy and safety in moderate-to-severe uncontrolled asthma. N Engl J Med. 2018;378(26):2486-2496.
Rabe KF, Nair P, Brusselle G, et al. Efficacy and safety of dupilumab in glucocorticoid-dependent severe asthma. N Engl J Med. 2018;378(26):2475-2485.
Bachert C, Han JK, Desrosiers M, et al. Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials. Lancet. 2019;394(10209):1638-1650.
Kabesch M, Schedel M, Carr D, et al. IL-4/IL-13 pathway genetics strongly influence serum IgE levels and childhood asthma. J Allergy Clin Immunol. 2006;117(2):269-274.
Corren J, Castro M, O'Riordan T, et al. Dupilumab efficacy in patients with uncontrolled, moderate-to-severe allergic asthma. J Allergy Clin Immunol Pract. 2020;8(2):516-526.
Heeb LEM, Egholm C, Boyman O. Evolution and function of interleukin-4 receptor signaling in adaptive immunity and neutrophils. Genes Immun. 2020;21(3):143-149.
Kubo M. Innate and adaptive type 2 immunity in lung allergic inflammation. Immunol Rev. 2017;278(1):162-172.
Emma R, Morjaria JB, Fuochi V, Polosa R, Caruso M. Mepolizumab in the management of severe eosinophilic asthma in adults: current evidence and practical experience. Ther Adv Respir Dis. 2018;12:1753466618808490. https://doi.org/10.1177/1753466618808490
Chupp GL, Bradford ES, Albers FC, et al. Efficacy of mepolizumab add-on therapy on health-related quality of life and markers of asthma control in severe eosinophilic asthma (MUSCA): a randomised, double-blind, placebo-controlled, parallel-group, multicentre, phase 3b trial. Lancet Respir Med. 2017;5(5):390-400.
Bel EH, Wenzel SE, Thompson PJ, et al. Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma. N Engl J Med. 2014;371(13):1189-1197.
Ortega HG, Liu MC, Pavord ID, et al. Mepolizumab treatment in patients with severe eosinophilic asthma. N Engl J Med. 2014;371(13):1198-1207.
Chapman KR, Albers FC, Chipps B, et al. The clinical benefit of mepolizumab replacing omalizumab in uncontrolled severe eosinophilic asthma. Allergy. 2019;74(9):1716-1726.
Humbert M, Albers FC, Bratton DJ, et al. Effect of mepolizumab in severe eosinophilic asthma according to omalizumab eligibility. Respir Med. 2019;154:69-75.
Pérez de Llano LA, Dacal Rivas D, Cosío BG. Mepolizumab and reslizumab, two different options for severe asthma patients with prior failure to omalizumab. Allergy. 2020;75(4):940-942.
Moore WC, Meyers DA, Wenzel SE, et al. Identification of asthma phenotypes using cluster analysis in the Severe Asthma Research Program. Am J Respir Crit Care Med. 2010;181(4):315-323.
Bachert C, Humbert M, Hanania NA, et al. Staphylococcus aureus and its IgE-inducing enterotoxins in asthma: current knowledge [published online ahead of print, 2020 Jan 24]. Eur Respir J. 2020;1901592: https://doi.org/10.1183/13993003.01592-2019
Boonpiyathad T, Sözener ZC, Satitsuksanoa P, Akdis CA. Immunologic mechanisms in asthma. Semin Immunol. 2019;46:101333.
Teufelberger AR, Nordengrün M, Braun H, et al. The IL-33/ST2 axis is crucial in type 2 airway responses induced by Staphylococcus aureus-derived serine protease-like protein D. J Allergy Clin Immunol. 2018;141(2):549-559.e7.
Chanez P, Contin-Bordes C, Garcia G, et al. Omalizumab-induced decrease of FcξRI expression in patients with severe allergic asthma. Respir Med. 2010;104:1608-1617.
Takaku Y, Soma T, Nishihara F, et al. Omalizumab attenuates airway inflammation and interleukin-5 production by mononuclear cells in patients with severe allergic asthma. Int Arch Allergy Immunol. 2013;161:S107-S117.
Noga O, Hanf G, Brachmann I, et al. Effect of omalizumab treatment on peripheral eosinophil and T-lymphocyte function in patients with allergic asthma. J Allergy Clin Immunol. 2006;117(6):1493-1499.
Roth M, Tamm M. The effects of omalizumab on IgE-induced cytokine synthesis by asthmatic airway smooth muscle cells. Ann. Allergy Asthma Immunol. 2010;104:152-160.
van Rensen ELJ, Evertse CE, van Schadewijk W, et al. Eosinophils in bronchial mucosa of asthmatics after allergen challenge: effect of anti-IgE treatment. Allergy. 2009;64(1):72-80.
Djukanović R, Wilson SJ, Kraft M, et al. Effects of treatment with anti-immunoglobulin E antibody omalizumab on airway inflammation in allergic asthma. Am J Respir Crit Care Med. 2004;170(6):583-593.
Massanari M, Holgate ST, Busse WW, Jimenez P, Kianifard F, Zeldin R. Effect of omalizumab on peripheral blood eosinophilia in allergic asthma. Respir Med. 2010;104(2):188-196.
Maggi L, Rossettini B, Montaini G, et al. Omalizumab dampens type 2 inflammation in a group of long-term treated asthma patients and detaches IgE from FcεRI. Eur J Immunol. 2018;48(12):2005-2014.
Domingo C, Pomares X, Angril N, Rudi N, Amengual MJ, Mirapeix RM. Effectiveness of omalizumab in non-allergic severe asthma. J Biol Regul Homeost Agents. 2013;27(1):45-53.
de Llano LP, Vennera Mdel C, Álvarez FJ, et al. Effects of omalizumab in non-atopic asthma: results from a Spanish multicenter registry. J Asthma. 2013;50(3):296-301.
Bourgoin-Heck M, Amat F, Trouvé C, et al. Omalizumab could be effective in children with severe eosinophilic non-allergic asthma. Pediatr Allergy Immunol. 2018;29(1):90-99.
Busse W, Spector S, Rosén K, Wang Y, Alpan O. High eosinophil count: a potential biomarker for assessing successful omalizumab treatment effects. J Allergy Clin Immunol. 2013;132(2):485-486.
Hanania NA, Wenzel S, Rosén K, et al. Exploring the effects of omalizumab in allergic asthma: an analysis of biomarkers in the EXTRA study. Am J Respir Crit Care Med. 2013;187(8):804-811.
Casale TB, Chipps BE, Rosén K, et al. Response to omalizumab using patient enrichment criteria from trials of novel biologics in asthma. Allergy. 2018;73(2):490-549.
Casale TB, Luskin AT, Busse W, et al. Omalizumab effectiveness by biomarker status in patients with asthma: evidence from PROSPERO, a prospective real-world study. J Allergy Clin Immunol Pract. 2019;7(1):156-164.
Humbert M, Taillé C, Mala L, et al. Omalizumab effectiveness in patients with severe allergic asthma according to blood eosinophil count: the STELLAIR study. Eur Respir J. 2018;51(5):1702523.
Lieberman PL, Jones I, Rajwanshi R, Rosén K, Umetsu DT. Anaphylaxis associated with omalizumab administration: Risk factors and patient characteristics. J Allergy Clin Immunol. 2017;140(6):1734-1736.e4.
Gill MA, Bajwa G, George TA, et al. Counter-regulation between the FcepsilonRI pathway and antiviral responses in human plasmacytoid dendritic cells. J Immunol. 2010;184:5999-6006.
Gill MA, Liu AH, Calatroni A, et al. Enhanced plasmacytoid dendritic cell antiviral responses after omalizumab. J Allergy Clin Immunol. 2018;141(5):1735-1743.
Efthimiou J, Poll C, Barnes PJ. Dual mechanism of action of T2 inhibitor therapies in virally induced exacerbations of asthma: evidence for a beneficial counter-regulation. Eur Respir J. 2019;54(1):1802390.
Teach SJ, Gill MA, Togias A, et al. Preseasonal treatment with either omalizumab or an inhaled corticosteroid boost to prevent fall asthma exacerbations. J Allergy Clin Immunol. 2015;136(6):1476-1485.
Busse WW, Morgan WJ, Gergen PJ, et al. Randomized trial of omalizumab (anti-IgE) for asthma in inner-city children. N Engl J Med. 2011;364(11):1005-1015.
Chipps BE, Figliomeni M, Spector S. Omalizumab: an update on efficacy and safety in moderate-to-severe allergic asthma. Allergy Asthma Proc. 2012;33(5):377-385.
Hanania NA, Alpan O, Hamilos DL, et al. Omalizumab in severe allergic asthma inadequately controlled with standard therapy: a randomized trial. Ann Intern Med. 2011;154(9):573-582.
Lanier BQ, Corren J, Lumry W, Liu J, Fowler-Taylor A, Gupta N. Omalizumab is effective in the long-term control of severe allergic asthma. Ann Allergy Asthma Immunol. 2003;91(2):154-159.
Ayres J, Higgins B, Chilvers ER, Ayre G, Blogg M, Fox H. Efficacy and tolerability of anti-immunoglobulin E therapy with omalizumab in patients with poorly controlled (moderate-to-severe) allergic asthma. Allergy. 2004;59(7):701-708.
Vignola AM, Humbert M, Bousquet J, et al. Efficacy and tolerability of anti-immunoglobulin E therapy with omalizumab in patients with concomitant allergic asthma and persistent allergic rhinitis: SOLAR. Allergy. 2004;59(7):709-717.
Humbert M, Beasley R, Ayres J, et al. Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE. Allergy. 2005;60(3):309-316.
Lanier B, Bridges T, Kulus M, Taylor AF, Berhane I, Vidaurre CF. Omalizumab for the treatment of exacerbations in children with inadequately controlled allergic (IgE-mediated) asthma. J Allergy Clin Immunol. 2009;124(6):1210-1216.
Liddament M, Husten J, Estephan T, et al. Higher Binding Affinity and in vitro Potency of Reslizumab for Interleukin-5 Compared With Mepolizumab. Allergy Asthma Immunol Res. 2019;11(2):291-298.
Matera MG, Rogliani P, Calzetta L, Cazzola M. Pharmacokinetic/pharmacodynamic profile of reslizumab in asthma. Expert Opin Drug Metab Toxicol. 2018;14(2):239-245.
Virchow JC, Katial R, Brusselle GG, et al. Safety of reslizumab in uncontrolled asthma with eosinophilia: a pooled analysis from 6 trials. J Allergy Clin Immunol Pract. 2020;8(2):540-548.
Castro M, Mathur S, Hargreave F, et al. Reslizumab for poorly controlled, eosinophilic asthma: a randomized, placebo-controlled study. Am J Respir Crit Care Med. 2011;184(10):1125-1132.
Castro M, Zangrilli J, Wechsler ME, et al. Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials. Lancet Respir Med. 2015;3(5):355-366.
Corren J, Weinstein S, Janka L, Zangrilli J, Garin M. Phase 3 study of reslizumab in patients with poorly controlled asthma: effects across a broad range of eosinophil counts. Chest. 2016;150(4):799-810.
Bjermer L, Lemiere C, Maspero J, Weiss S, Zangrilli J, Germinaro M. Reslizumab for inadequately controlled asthma with elevated blood eosinophil levels: a randomized phase 3 study. Chest. 2016;150(4):789-798.
Shaker M, Briggs A, Dbouk A, Dutille E, Oppenheimer J, Greenhawt M. Estimation of health and economic benefits of clinic versus home administration of omalizumab and mepolizumab. J Allergy Clin Immunol Pract. 2020;8(2):565-572.
Kabata H, Flamar AL, Mahlakõiv T, et al. Targeted deletion of the TSLP receptor reveals cellular mechanisms that promote type 2 airway inflammation [published online ahead of print, 2020 Feb 17]. Mucosal Immunol. 2020. https://doi.org/10.1038/s41385-020-0266-x
Wang W, Li Y, Lv Z, et al. Bronchial allergen challenge of patients with atopic asthma triggers an alarmin (IL-33, TSLP, and IL-25) response in the airways epithelium and submucosa. J Immunol. 2018;201(8):2221-2231.
Li Y, Wang W, Lv Z, et al. Elevated expression of IL-33 and TSLP in the airways of human asthmatics in vivo: a potential biomarker of severe refractory disease. J Immunol. 2018;200(7):2253-2262.
Huang YC, Weng CM, Lee MJ, Lin SM, Wang CH, Kuo HP. Endotypes of severe allergic asthma patients who clinically benefit from anti-IgE therapy. Clin Exp Allergy. 2019;49(1):44-53.
Corren J, Parnes JR, Wang L, et al. Tezepelumab in adults with uncontrolled asthma. N Engl J Med. 2017;377(10):936-946.
https://www.fdanews.com/articles/188355-fda-awards-astrazeneca-and-amgens-tezepelumab-breakthrough-designation.
https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-001549-13/.
https://www.sanofi.com/en/media-room/press-releases/2019/2019-06-21-07-00-00.
Lightwood D, Tservistas M, Zehentleitner M, et al. Efficacy of an inhaled IL-13 antibody fragment in a model of chronic asthma. Am J Respir Crit Care Med. 2018;198(5):610-619.
Harris JM, Maciuca R, Bradley MS, et al. A randomized trial of the efficacy and safety of quilizumab in adults with inadequately controlled allergic asthma. Respir Res. 2016;17:29.
Wildfire JJ, Gergen PJ, Sorkness CA, et al. Development and validation of the Composite Asthma Severity Index-an outcome measure for use in children and adolescents. J Allergy Clin Immunol. 2012;129(3):694-701.
Fitzpatrick AM, Szefler SJ, Mauger DT, et al. Development and initial validation of the Asthma Severity Scoring System (ASSESS). J Allergy Clin Immunol. 2020;145(1):127-139.
d'Ancona G, Kavanagh J, Roxas C, et al. Adherence to inhaled corticosteroids and clinical outcomes in mepolizumab therapy for severe asthma [published online ahead of print, 2020 Feb 20]. Eur Respir J. 2020;1902259.
Bagnasco D, Menzella F, Caminati M, et al. Efficacy of mepolizumab in patients with previous omalizumab treatment failure: Real-life observation. Allergy. 2019;74(12):2539-2541.
Matsuno O, Minamoto S. Eosinophils depletion therapy for severe asthma management following favorable response to mepolizumab. Respir Med Case Rep. 2019;28:100899.
Mukherjee M, Aleman Paramo F, Kjarsgaard M, et al. Weight-adjusted intravenous reslizumab in severe asthma with inadequate response to fixed-dose subcutaneous mepolizumab. Am J Respir Crit Care Med. 2018;197(1):38-46.
Rup B, Pallardy M, Sikkema D, et al. Standardizing terms, definitions and concepts for describing and interpreting unwanted immunogenicity of biopharmaceuticals: recommendations of the Innovative Medicines Initiative ABIRISK consortium. Clin Exp Immunol. 2015;181(3):385-400.
Smith SG, Chen R, Kjarsgaard M, et al. Increased numbers of activated group 2 innate lymphoid cells in the airways of patients with severe asthma and persistent airway eosinophilia. J Allergy Clin Immunol. 2016;137(1):75-86.e8.
Mukherjee M, Bulir DC, Radford K, et al. Sputum autoantibodies in patients with severe eosinophilic asthma. J Allergy Clin Immunol. 2018;141(4):1269-1279.
Mukherjee M, Lim HF, Thomas S, et al. Airway autoimmune responses in severe eosinophilic asthma following low-dose Mepolizumab therapy. Allergy Asthma Clin Immunol. 2017;13:2.
Gibson PG, Yang IA, Upham JW, et al. Effect of azithromycin on asthma exacerbations and quality of life in adults with persistent uncontrolled asthma (AMAZES): a randomised, double-blind, placebo-controlled trial. Lancet. 2017;390(10095):659-668.
Matera MG, Page CP, Calzetta L, Rogliani P, Cazzola M. Pharmacology and therapeutics of bronchodilators revisited. Pharmacol Rev. 2020;72(1):218-252.
Bonta PI, Chanez P, Annema JT, Shah PL, Niven R. Bronchial thermoplasty in severe asthma: best practice recommendations from an expert panel. Respiration. 2018;95(5):289-300.
Mepolizumab for treating severe refractory eosinophilic asthma. Technology appraisal guidance [TA431]. National Institute for Health and Clinical Excellence. Published: 25/01/2017. https://www.nice.org.uk/guidance/ta431/chapter/1-recommendations.
Wang FP, Liu T, Lan Z, Li SY, Mao H. Efficacy and safety of anti-interleukin-5 therapy in patients with asthma: a systematic review and meta-analysis. PLoS One. 2016;11(11):e0166833.
Ramirez-Carrozzi V, Sambandam A, Zhou M, et al. Combined blockade of the IL-13 and IL-33 pathways leads to a greater inhibition of type 2 inflammation over inhibition of either pathway alone. J Allergy Clin Immunol. 2017;139(2):705-708.
Zhang F-Q, Han X-P, Zhang F, et al. Therapeutic efficacy of a co-blockade of IL-13 and IL-25 on airway inflammation and remodeling in a mouse model of asthma. Int Immunopharmacol. 2017;46:133-140.
Venkataramani S, Low S, Weigle B, et al. Design and characterization of Zweimab and Doppelmab, high affinity dual antagonistic anti-TSLP/IL13 bispecific antibodies. Biochem Biophys Res Commun. 2018;504(1):19-24.
Roth-Walter F, Adcock IM, Benito-Villalvilla C, et al. Comparing biologicals and small molecule drug therapies for chronic respiratory diseases: An EAACI Taskforce on Immunopharmacology position paper. Allergy. 2019;74(3):432-448.
Khindri S, Cahn A, Begg M, et al. A multicentre, randomized, double-blind, placebo-controlled, crossover study to investigate the efficacy, safety, tolerability, and pharmacokinetics of repeat doses of inhaled nemiralisib in adults with persistent. Uncontrolled Asthma. J Pharmacol Exp Ther. 2018;367(3):405-413.
Calbet M, Ramis I, Calama E, et al. Novel inhaled Pan-JAK inhibitor, LAS194046, reduces allergen-induced airway inflammation, late asthmatic response, and pSTAT activation in brown Norway rats. J Pharmacol Exp Ther. 2019;370(2):137-147.
Zak M, Hanan EJ, Lupardus P, et al. Discovery of a class of highly potent Janus Kinase 1/2 (JAK1/2) inhibitors demonstrating effective cell-based blockade of IL-13 signaling. Bioorg Med Chem Lett. 2019;29(12):1522-1531.
Sze E, Bhalla A, Nair P. Mechanisms and therapeutic strategies for non-T2 asthma. Allergy. 2020;75(2):311-325.
Menzies-Gow A, Bafadhel M, Busse WW, et al. An expert consensus framework for asthma remission as a treatment goal. J Allergy Clin Immunol. 2020;145(3):757-765.
Netea MG, Joosten LAB, Latz E, et al. Trained immunity: A program of innate immune memory in health and disease. Science. 2016;352(6284):aaf1098.
van de Veen W, Akdis M. The use of biologics for immune modulation in allergic disease. J Clin Invest. 2019;130(4):1452-1462.
Lunjani N, Satitsuksanoa P, Lukasik Z, Sokolowska M, Eiwegger T, O'Mahony L. Recent developments and highlights in mechanisms of allergic diseases: Microbiome. Allergy. 2018;73(12):2314-2327.
Chung KF. Potential role of the lung microbiome in shaping asthma phenotypes. Ann Am Thorac Soc. 2017;14(Supplement_5):S326-S331.
Michalovich D, Rodriguez-Perez N, Smolinska S, et al. Obesity and disease severity magnify disturbed microbiome-immune interactions in asthma patients. Nat Commun. 2019;10(1):5711.
Venter C, Meyer RW, Nwaru BI, et al. EAACI position paper: Influence of dietary fatty acids on asthma, food allergy, and atopic dermatitis. Allergy. 2019;74(8):1429-1444.
Pfaar O, Agache I, Blay F, et al. Perspectives in allergen immunotherapy: 2019 and beyond. Allergy. 2019;74(Suppl 108):3-25.
Agache I, Lau S, Akdis CA, et al. EAACI Guidelines on Allergen Immunotherapy: House dust mite-driven allergic asthma. Allergy. 2019;74(5):855-873.
Jutel M, Van de Veen W, Agache I, Azkur KA, Akdis M, Akdis CA. Mechanisms of allergen-specific immunotherapy and novel ways for vaccine development. Allergol Int. 2013;62(4):425-433.
Ravin KA, Loy M. The eosinophil in infection. Clin Rev Allergy Immunol. 2016;50(2):214-227.
Jacobsen EA, Helmers RA, Lee JJ, Lee NA. The expanding role(s) of eosinophils in health and disease. Blood. 2012;120(19):3882-3890.
Marichal T, Mesnil C, Bureau F. Homeostatic eosinophils: characteristics and functions. Front Med. 2017;4:101.
Shah K, Ignacio A, McCoy KD, Harris NL. The emerging roles of eosinophils in mucosal homeostasis. Mucosal Immunol. 2020. https://doi.org/10.1038/s41385-020-0281-y
Wen T, Rothenberg ME. The regulatory function of eosinophils. Microbiol Spectr. 2016;4(5).
Jiménez-Saiz R, Anipindi VC, Galipeau H, et al. Microbial regulation of enteric eosinophils and its impact on tissue remodeling and Th2 immunity. Front Immunol. 2020;11:155.
Mesnil C, Raulier S, Paulissen G, et al. Lung-resident eosinophils represent a distinct regulatory eosinophil subset. J Clin Invest. 2016;126:3279-3295.
Pellizzari G, Hoskin C, Crescioli S, et al. IgE re-programs alternatively-activated human macrophages towards pro-inflammatory anti-tumoural states. EBioMedicine. 2019;43:67-81.
Jensen-Jarolim E, Bax HJ, Bianchini R, et al. AllergoOncology - the impact of allergy in oncology: EAACI position paper. Allergy. 2017;72(6):866-887.
Crawford G, Hayes MD, Seoane RC, et al. Epithelial damage and tissue γδ T cells promote a unique tumor-protective IgE response. Nat Immunol. 2018;19(8):859-870.
Ferastraoaru D, Rosenstreich D. IgE deficiency and prior diagnosis of malignancy: Results of the 2005-2006 National Health and Nutrition Examination Survey. Ann Allergy Asthma Immunol. 2018;121(5):613-618.
Grencis RK. Immunity to helminths: resistance, regulation, and susceptibility to gastrointestinal nematodes. Annu Rev Immunol. 2015;33:201-225.
Chen F, Liu Z, Wu W, et al. An essential role for TH2-type responses in limiting acute tissue damage during experimental helminth infection. Nat Med. 2012;18(2):260-266.
Minutti CM, Jackson-Jones LH, García-Fojeda B, et al. Local amplifiers of IL-4Rα-mediated macrophage activation promote repair in lung and liver. Science. 2017;356(6342):1076-1080.
DeAngelis RA, Markiewski MM, Kourtzelis I, et al. A complement-IL-4 regulatory circuit controls liver regeneration. J Immunol. 2012;188(2):641-648.
ISAR Study Group. International severe asthma registry: mission statement. Chest. 2019;157(4):805-814.
Senna G, Guerriero M, Paggiaro PL, et al. SANI-Severe Asthma Network in Italy: a way forward to monitor severe asthma. Clin Mol Allergy. 2017;15:9.
Taillé C, Pison C, Nocent C, et al. Patients in the IDEAL cohort: a snapshot of severe asthma in France. Rev Mal Respir. 2019;36(2):179-190.
Jeffery MM, Shah ND, Karaca-Mandic P, Ross JS, Rank MA. Trends in omalizumab utilization for asthma: evidence of suboptimal patient selection. J Allergy Clin Immunol Pract. 2018;6(5):1568-1577.
Llanos JP, Bell CF, Packnett E, et al. Real-world characteristics and disease burden of patients with asthma prior to treatment initiation with mepolizumab or omalizumab: a retrospective cohort database study. J Asthma Allergy. 2019;12:43-58.
Inselman JW, Jeffery MM, Maddux JT, Shah ND, Rank MA. Trends and disparities in asthma biologic use in the United States. J Allergy Clin Immunol Pract. 2020;8(2):549-554.e1.
Singh H, Peters JI, Kaur Y, Maselli DJ, Diaz JD. Long-term evaluation of response to omalizumab therapy in real life by a novel multimodular approach: the Real-life Effectiveness of Omalizumab Therapy (REALITY) study. Ann Allergy Asthma Immunol. 2019;123(5):476-482.
Abrams EM, Becker AB, Szefler SJ. Current state and future of biologic therapies in the treatment of asthma in children. Pediatr Allergy Immunol Pulmonol. 2018;31(3):119-131.
Akdis CA, Arkwright PD, Brüggen MC, et al. Type 2 immunity in the skin and lungs. Allergy. 2020;75(7):1582-1605. https://doi.org/10.1111/all.14318
Cusack RP, Sahadevan A, Lane SJ. Qualitative effects of omalizumab on concomitant IgE-mediated disease in a severe asthmatic population: a real life observational study. QJM. 2016;109(9):601-604.
Singhania A, Rupani H, Jayasekera N, et al. Altered epithelial gene expression in peripheral airways of severe asthma. PLoS One. 2017;12(1):e0168680.
Gafar F, Boudewijn IM, Cox CA, et al. Predictors of clinical response to extrafine and non-extrafine particle inhaled corticosteroids in smokers and ex-smokers with asthma. Respir Res. 2018;19(1):256.
Castro M, Rabe KF, Corren J, et al. Dupilumab improves lung function in patients with uncontrolled, moderate-to-severe asthma. ERJ Open Res. 2020;6(1):00204-2019.
Sposato B, Camiciottoli G, Bacci E, et al. Mepolizumab effectiveness on small airway obstruction, corticosteroid sparing and maintenance therapy step-down in real life. Pulm Pharmacol Ther. 2020;61:101899.
Mathioudakis AG, Custovic A, Deschildre A, et al. Research priorities in pediatric asthma: results of a global survey of multiple stakeholder groups by the Pediatric Asthma in Real Life (PeARL) think tank. J Allergy Clin Immunol Pract. 2020;8(6):1953-1960.e9
Szefer S. Asthma across the lifespan: time for a paradigm shift. J Allergy Clin Immunol. 2018;142:773-780.